Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes

Journal of Immunology

Volumn 176, Issue 9, 2006, Pages 5284-5292

  Coward, William R ^a   Marei, Ayman ^a   Yang, AiLi ^a   Vasa Nicotera, Mariuca M ^a   Chow, Sek C ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CHOLESTEROL; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; MEVALONIC ACID; MITOGENIC AGENT; NEUTRALIZING ANTIBODY; PHYTOHEMAGGLUTININ; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

EID: 33646016282     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.9.5284     Document Type: Article

References (45)

1. Tobert, J. A. 2003. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2: 517-526.
2. Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N. Engl. J. Med. 335: 1001-1009.
3. Downs, J. R., M. Clearfield, S. Weis, E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer, and A. M. Gotto, Jr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels-results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 279: 1615-1622.
4. Maron, D. J., S. Fazio, and M. F. Linton. 2000. Current perspectives on statins. Circulation 101: 207-213.
5. Weitz-Schmidt, G., K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7: 687-692.
6. Kwak, B., F. Mulhaupt, N. Veillard, G. Pelli, and F. Mach. 2001. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-γ induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly. 131: 41-46.
7. Reape, T. J., and P. H. Groot. 1999. Chemokines and atherosclerosis. Atherosclerosis 147: 213-225.
8. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
9. Aktas, O., S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197: 725-733.
10. Leung, B. P., N. Sattar, A. Crilly, M. Prach, D. W. McCarey, H. Payne, R. Madhok, C. Campbell, J. A. Gracie, F. Y. Liew, and I. B. McInnes. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170: 1524-1530.
11. McKay, A., B. P. Leung, I. B. McInnes, N. C. Thomson, and F. Y. Liew. 2004. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J. Immunol. 172: 2903-2908.
12. Montero, M. T., O. Hernandez, Y. Suarez, J. Matilla, A. J. Ferruelo, J. Martinez-Botas, D. Gomez-Coronado, and M. A. Lasuncion. 2000. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153: 303-313.
13. Matsumoto, M., D. Einbaus, E. S. Gold, and A. Aderem. 2004. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol. 172: 7377-7384.
14. Sadeghi, M. M., M. Collinge, R. Pardi, and J. R. Bender. 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165: 2712-2718.
15. Sun, D., and G. Fernandes. 2003. Lovastatin inhibits bone marrow-derived dendritic cell maturation and up-regulates proinflammatory cytokine production. Cell. Immunol. 223: 52-62.
16. Monick, M. M., L. S. Powers, N. S. Butler, and G. W. Hunninghake. 2003. Inhibition of Rho family GTPases results in increased TNF-α production after lipopolysaccharide exposure. J. Immunol. 171: 2625-2630.
17. LeBlanc, R., T. Hideshima, L. P. Catley, R. Shringarpure, R. Burger, N. Mitsiades, C. Mitsiades, P. Cheema, D. Chauhan, P. G. Richardson, et al. 2004. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103: 1787-1790.
18. + T cells based on cytokine secretion. Methods 31: 150-159.
19. Desombere, I., P. Meuleman, H. Rigole, A. Willems, J. Irsch, and G. Leroux-Roels. 2004. The interferon γ secretion assay: a reliable tool to study interferon γ production at the single cell level. J. Immunol. Methods 286: 167-185.
20. Coward, W., and S. C. Chow. 2006. Effect of atorvastatin on Th1 and Th2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis. In press.
21. Neuhaus, O., S. Strasser-Fuchs, F. Fazekas, B. C. Kieseier, G. Niederwieser, H. P. Hartung, and J. J. Archelos. 2002. Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology 59: 990-997.
22. Ghayur, T., S. Banerjee, M. Hugunin, D. Butler, L. Herzog, A. Carter, L. Quintal, L. Sekut, R. Talanlan, M. Paskind, et al. 1997. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 386: 619-623.
23. Gu, Y., K. Kuida, H. Tsutsui, G. Ku, K. Hsiao, M. A. Fleming, N. Hayashi, K. Higashino, H. Okamura, K. Nakanishi, et al. 1997. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275: 206-209.
24. Robertson, M. J., and J. Ritz. 1996. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1: 88-97.
25. Yoshimoto, T., K. Takeda, T. Tanaka, K. Ohkusu, S. Kashiwamura, H. Okamura, S. Akira, and K. Nakanishi. 1998. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. 161: 3400-3407.
26. Miossec, C., M.-C. Deconen, F. Fassy, and A. Diu-Hercend. 1996. Use of monoclonal antibodies to study interleukin-1β-converting enzyme expression: only precursor forms are detected in interleukin-1β-secreting cells. Eur. J. Immunol. 26: 1032-1042.
27. Jones, P., S. Kafonek, I. Laurora, and D. Hunninghake. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81: 582-587.
28. - T cell subsets to express IL-18 receptor and produce IFN-γ in response to IL-18. J. Immunol. 160: 3759-3765.
29. Hogqvist, K. A., M. A. Nett, E. R. Unanue, and D. D. Chaplin. 1991. Interleukin 1 is processed and released during apoptosis. Proc. Natl. Acad. Sci. USA 88: 8485-8489.
30. Perregaux, D., and C. A. Gabel. 1994. Interleukin-1β maturation and release in response to ATP and nigericin: evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 269: 15195-15203.
31. Montero, M. T., J. Matilla, E. Gomez-Mampaso, and M. A. Lasuncion. 2004. Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis. J. Immunol. 173:4936-4944.
32. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature 343: 425-430.
33. Houten, S. M., W. Kuis, M. Duran, T. J. de Koning, A. van Royen-Kerkhof, G. J. Romeijn, J. Frenkel, L. Dorland, M. M. de Barse, W. A. Huijbers, et al. 1999. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22: 175-177.
34. Houten, S. M., G. J. Romeijn, J. Koster, R. G. Gray, P. Darbyshire, G. P. Smit, J. B. de Klerk, M. Duran, K. M. Gibson, R. J. Wanders, and H. R. Waterham. 1999. Identification and characterization of three novel missense mutations in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of isoprene biosynthesis. Hum. Mol. Genet. 8: 1523-1528.
35. Drenth, J. P., L. Cuisset, G. Grateau, C. Vasseur, S. D. van de Velde-Visser, J. G. de Jong, J. S. Beckmann, J. W. van der Meer, and M. Delpech. 1999. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome: International Hyper-IgD Study Group. Nat. Genet. 22: 178-181.
36. Frenkel, J., G. T. Rijkers, S. H. Mandey, S. W. Buurman, S. M. Houten, R. J. Wanders, H. R. Waterham, and W. Kuis. 2002. Lack of isoprenoid products raises ex vivo interleukin-1β secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 46: 2794-2803.
37. Hoffmann, G. F., C. Charpentier, E. Mayatepek, J. Mancini, M. Leichsenring, K. M. Gibson, P. Divry, M. Hrebicek, W. Lehnert, K. Sartor, et al. 1993. Clinical and biochemical phenotypes in 11 patients with mevalonic aciduria. Pediatrics 91: 915-921.
38. Corsini, A., S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini. 1999. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84: 413-428.
39. Posvar, E. L., L. L. Radulovic, D. D. Cilla, Jr., L. R. Whitfield, and A. J. Sedman. 1996. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J. Clin. Pharmacol. 36: 728-731.
40. Jacobson, T. A. 2004. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. 94: 1140-1146.
41. Ault, A. 1997. FDA warns of potential protease-inhibitor link to hyperglycaemia. Lancet 349: 1819.
42. Murillas, J., T. Martin, A. Ramos, and J. L. Portera. 1999. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS 13: 1424-1425.
43. Hsyu, P. H., M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis, and B. M. Kerr. 2001. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. 45: 3445-3450.
44. Clotet, B., and E. Negredo. 2003. HIV protease inhibitors and dyslipidemia. AIDS Rev. 5: 19-24.
45. Clotet, B., M. van der Valk, E. Negredo, and P. Reiss. 2003. Impact of nevirapine on lipid metabolism. J. Acquired Immune Defic. Syndr. 34(Suppl. 1): S79-S84.